These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27760957)

  • 1. [Administration of Immune Checkpoint Inhibitor for Cancer except for Melanoma and Lung Cancer].
    Takeda T; Hattori N; Takeda T; Noda T; Takeda H
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1271-1273. PubMed ID: 27760957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab: targeting PD-1 to bolster antitumor immunity.
    Brahmer JR; Hammers H; Lipson EJ
    Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
    Gettinger SN; Horn L; Gandhi L; Spigel DR; Antonia SJ; Rizvi NA; Powderly JD; Heist RS; Carvajal RD; Jackman DM; Sequist LV; Smith DC; Leming P; Carbone DP; Pinder-Schenck MC; Topalian SL; Hodi FS; Sosman JA; Sznol M; McDermott DF; Pardoll DM; Sankar V; Ahlers CM; Salvati M; Wigginton JM; Hellmann MD; Kollia GD; Gupta AK; Brahmer JR
    J Clin Oncol; 2015 Jun; 33(18):2004-12. PubMed ID: 25897158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    Ozaki Y; Shindoh J; Miura Y; Nakajima H; Oki R; Uchiyama M; Masuda J; Kinowaki K; Kondoh C; Tanabe Y; Tanaka T; Haruta S; Ueno M; Kitano S; Fujii T; Udagawa H; Takano T
    BMC Cancer; 2017 Nov; 17(1):778. PubMed ID: 29162045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ
    J Clin Oncol; 2015 May; 33(13):1430-7. PubMed ID: 25452452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Yoshikawa S; Kiyohara Y; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Mochizuki T; Yamaguchi K; Akiyama Y
    Anticancer Res; 2017 Mar; 37(3):1321-1328. PubMed ID: 28314298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab: Immunotherapy in Malignant Melanoma.
    Bayless H; Schneider S
    Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
    J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
    Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C
    J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology and clinical applications of CD40 in cancer treatment.
    Fonsatti E; Maio M; Altomonte M; Hersey P
    Semin Oncol; 2010 Oct; 37(5):517-23. PubMed ID: 21074067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
    Renner A; Burotto M; Rojas C
    J Glob Oncol; 2019 Jul; 5():1-5. PubMed ID: 31348737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death 1 immune checkpoint inhibitors.
    Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Cerebellar Ataxia Induced by Nivolumab.
    Kawamura R; Nagata E; Mukai M; Ohnuki Y; Matsuzaki T; Ohiwa K; Nakagawa T; Kohno M; Masuda R; Iwazaki M; Takizawa S
    Intern Med; 2017; 56(24):3357-3359. PubMed ID: 29249765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
    LoRusso P; Jänne PA; Oliveira M; Rizvi N; Malburg L; Keedy V; Yee L; Copigneaux C; Hettmann T; Wu CY; Ang A; Halim AB; Beckman RA; Beaupre D; Berlin J
    Clin Cancer Res; 2013 Jun; 19(11):3078-87. PubMed ID: 23591447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
    J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
    Gibney GT; Kudchadkar RR; DeConti RC; Thebeau MS; Czupryn MP; Tetteh L; Eysmans C; Richards A; Schell MJ; Fisher KJ; Horak CE; Inzunza HD; Yu B; Martinez AJ; Younos I; Weber JS
    Clin Cancer Res; 2015 Feb; 21(4):712-20. PubMed ID: 25524312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of Immune Checkpoint Inhibitor Combined with Dendritic Cell Therapy and Hyperthermia].
    Takeda T; Kubota Y; Takeda T; Tanaka C; Morita S; Hattori N; Takeda H; Yokoyama Y; Yamamoto H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1472-1474. PubMed ID: 30382049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.